Search

Displaying results 2561 - 2570 of 10000 in total
  1. Drug

    Dapagliflozin

    go.drugbank.com/drugs/DB06292
    ApprovedInvestigational

    [A261601] Dapagliflozin was originally approved by the FDA on Jan 08, 2014, to improve glycemic control in adults with type 2 diabetes in conjunction with diet and exercise. … [L48251] It was later approved to reduce the risk of kidney function decline, kidney failure, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease in April

    Synonyms: (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triolMixtures: XIGDUO® XR 10MG/1000MG TABLETAS RECUBIERTAS DE LIBERACION PROLONGADA, XIGDUO® XR 10MG/1000MG TABLETAS RECUBIERTAS DE LIBERACION PROLONGADA
  2. Indication

    Primary Hemophagocytic Lymphohistiocytosis

    go.drugbank.com/conditions/DBCOND0063312
    Drugs: Emapalumab
    Synonyms: Genetic hemophagocytic lymphohistiocytosis, Genetic haemophagocytic lymphohistiocytosis
  3. Drug

    Prothrombin

    go.drugbank.com/drugs/DB11311
    ApprovedInvestigational

    Prothrombin Complex Concentrate (Human), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with

    Mixtures: Beriplex P/n 500, Beriplex P/n 1000Synonyms: Factor II, Factor II (prothrombin)
  4. Drug

    Capivasertib

    go.drugbank.com/drugs/DB12218
    ApprovedInvestigational

    Although endocrine-based therapy is the first line of treatment, resistance eventually emerges, leaving chemotherapy the only but often ineffective treatment left. … [A262021] The PIK3/AKT pathway is one of the most commonly activated pathways in breast cancer, mainly through the constitutively active mutation in AKT1, loss of function mutation in PTEN, a negative

    Categories: MATE 1 Inhibitors, MATE 2 Inhibitors
  5. Drug

    Nilutamide

    go.drugbank.com/drugs/DB00665
    ApprovedInvestigational

    Nilutamide is an antineoplastic hormonal agent primarily used in the treatment of prostate cancer. … Nilutamide is a pure, nonsteroidal anti-androgen with affinity for androgen receptors (but not for progestogen, estrogen, or glucocorticoid receptors).

    Synonyms: 5,5-Dimethyl-3-(α,α,α-trifluoro-4-nitro-m-tolyl)hydantoinCategories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring
  6. Drug

    Vadadustat

    go.drugbank.com/drugs/DB12255
    ApprovedInvestigational

    [L39610,L46936,L46951] Vadadustat was approved by the FDA in March 2024.[L50371] … [A244145,A244155] It was first approved in Japan in 2020,[L50371] and in April 2023, it was approved by the EMA for the treatment of symptomatic anemia associated with CKD in adults on chronic maintenance

    Synonyms: N-(5-(3-Chlorophenyl)-3-hydroxypyridine-2-carbonyl)glycine, Glycine, N-((5-(3-chlorophenyl)-3-hydroxy-2-pyridinyl)carbonyl)-Categories: Cytochrome P-450 CYP2B6 Inducers, Heterocyclic Compounds, 1-Ring
  7. Drug

    Diacetyl benzoyl lathyrol

    go.drugbank.com/drugs/DB11260
    Approved

    Diacetyl benzoyl lathyrol is an active ingredient in whitening creams. It is also reported to be a skin conditioning agent.

    Mixtures: The History Of Whoo Gongjinhyang Mi Luxury Bb, O HUI white-skin science white calming mask
  8. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    Two denosumab biosimilars—Wyost® (denosumab-bbdz) [L53063] and Jubbonti® (denosumab-bbdz)[L53058]—were approved by the FDA in March 2024 for all indications of the reference products Xgeva® and Prolia® … [A263066] Denosumab was approved by the FDA approved on June 2010 for the treatment of osteoporosis in postmenopausal women.

    Categories: Drugs for Treatment of Bone DiseasesProducts: PROLIA®, XGEVA® 120 MG/1.7 ML
  9. Drug

    Canakinumab

    go.drugbank.com/drugs/DB06168
    ApprovedInvestigational

    It is expressed in a murine Sp2/0-Ag14 cell line and comprised of two 447- (or 448-) residue heavy chains and two 214-residue light chains, with a molecular mass of 145157 Daltons when deglycosylated. … Canakinumab binds to human IL-1β and neutralizes its inflammatory activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1alpha or IL-1 receptor antagonist (IL-1ra).

    Categories: Interleukin-1 BlockersProducts: ILARIS® SOLUCIÓN INYECTABLE 150 MG/ ML, İLARİS 150 MG/ML ENJEKSİYONLUK ÇÖZELTİ, 1 ADET
  10. Drug

    Eucalyptus oil

    go.drugbank.com/drugs/DB11114
    Approved

    It is shown to be effective in reducing pain, swelling, and inflammation via its modulatory effect on the immune response. … Eucalyptus oil is a distilled oil derived from the leaves of the tree Eucalyptus.

    Mixtures: Cellzyme ON-TOX, Cellzyme ON-TOXSynonyms: Oil of eucalyptus